SPONSOR
Iovance Biotherapeutics, Inc.
Total Trials
2
Recruiting
2
Phases
Phase 3, Phase 1, Phase 2
Iovance Biotherapeutics, Inc. is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Metastatic Melanoma, Unresectable Melanoma, Melanoma, Ocular Melanoma.
The trial portfolio spans Phase 3, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Iovance Biotherapeutics, Inc.
How many clinical trials has Iovance Biotherapeutics, Inc. sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Iovance Biotherapeutics, Inc., of which 2 are actively recruiting participants. These trials cover conditions including Metastatic Melanoma, Unresectable Melanoma, Melanoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Iovance Biotherapeutics, Inc. research focus on?
Iovance Biotherapeutics, Inc. clinical trials span Metastatic Melanoma, Unresectable Melanoma, Melanoma, Ocular Melanoma. The research pipeline includes Phase 3, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Iovance Biotherapeutics, Inc. clinical trial?
To participate in a Iovance Biotherapeutics, Inc. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Iovance Biotherapeutics, Inc. trials with current recruitment status updated daily.
Clinical Trials by Iovance Biotherapeutics, Inc.
NCT05727904 Phase 3
Recruiting
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Metastatic Melanoma
NCT06940739 Phase 1, Phase 2
Recruiting
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
Unresectable Melanoma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology